The story of Viagra and its parent , copyright, presents a tangled picture for cautious investors. While the iconic drug initially generated enormous revenues , its exclusivity has ended, leading to generic alternatives flooding the arena. This reduction in cost presents a real hurdle for copyright and any fund considering a significant stake in th